Upstream Bio sets Phase 3 plans for verekitug in asthma and CRSwNP
After End-of-Phase 2 meetings with FDA, the company will run one pivotal trial in each indication using a 400mg dose every 12 weeks, starting Q1 2027.
SEC filing
Latest
3 stories
Friday, September 18
Tuesday, September 1
Tuesday, August 11
Upstream Bio reports Q2 2026 results, COPD enrollment complete, Phase 3 on track for Q1 2027
The company said end-of-Phase 2 talks with the FDA remain on schedule as it prepares Phase 3 trials in severe asthma and CRSwNP for verekitug.
SEC filing